Manufacturer of Controlled Substances, Notice of Registration; Morton Grove Pharmaceuticals, 5503 [2013-01592]

Download as PDF 5503 Federal Register / Vol. 78, No. 17 / Friday, January 25, 2013 / Notices Drug Schedule Dextropropoxyphene, bulk (non-dosage forms) (9273) .............................................................................................................................. Morphine (9300) .......................................................................................................................................................................................... Thebaine (9333) .......................................................................................................................................................................................... Levo-alphacetylmethadol (9648) ................................................................................................................................................................. Oxymorphone (9652) ................................................................................................................................................................................... Noroxymorphone (9668) .............................................................................................................................................................................. Racemethorphan (9732) .............................................................................................................................................................................. Alfentanil (9737) .......................................................................................................................................................................................... Remifentanil (9739) ..................................................................................................................................................................................... Sufentanil (9740) ......................................................................................................................................................................................... Carfentanil (9743) ........................................................................................................................................................................................ Tapentadol (9780) ....................................................................................................................................................................................... Fentanyl (9801) ........................................................................................................................................................................................... The company plans to manufacture small quantities of the listed controlled substances to make reference standards which will be distributed to their customers. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Cerilliant Corporation to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated Cerilliant Corporation to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems; verification of the company’s compliance with state and local laws; and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed. Dated: January 15, 2013. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. manufacturer of Gamma Hydroxybutyric Acid (2010), a basic class of controlled substance listed in schedule I. The company plans to manufacture the listed controlled substance for distribution to its customers. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a), and determined that the registration of Morton Grove Pharmaceuticals to manufacture the listed basic class of controlled substance is consistent with the public interest at this time. DEA has investigated Morton Grove Pharmaceuticals to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems; verification of the company’s compliance with state and local laws; and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic class of controlled substance listed. Dated: January 14, 2013. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 2013–01533 Filed 1–24–13; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE [FR Doc. 2013–01592 Filed 1–24–13; 8:45 am] Drug Enforcement Administration BILLING CODE 4410–09–P mstockstill on DSK4VPTVN1PROD with Manufacturer of Controlled Substances, Notice of Registration; Morton Grove Pharmaceuticals By Notice dated September 25, 2012, and published in the Federal Register on October 2, 2012, 77 FR 60144, Morton Grove Pharmaceuticals, 6451 Main Street, Morton Grove, Illinois 60053–2633, made application by letter to the Drug Enforcement Administration (DEA) to be registered as a bulk VerDate Mar<15>2010 18:39 Jan 24, 2013 Jkt 229001 PO 00000 Frm 00097 Fmt 4703 Sfmt 4703 II II II II II II II II II II II II II DEPARTMENT OF LABOR Office of the Secretary Agency Information Collection Activities; Submission for OMB Review; Comment Request; Statement of Expenditures and Financial Adjustment of Federal Funds for Unemployment Compensation for Federal Employees and ExServicemembers ACTION: Notice. The Department of Labor (DOL) is submitting the Employment and Training Administration (ETA) sponsored information collection request (ICR) titled, ‘‘Statement of Expenditures and Financial Adjustment of Federal Funds for Unemployment Compensation for Federal Employees and Ex-Servicemembers,’’ (Reporting Form ETA–191) to the Office of Management and Budget (OMB) for review and approval for continued use in accordance with the Paperwork Reduction Act (PRA) of 1995 (44 U.S.C. 3501 et seq.). DATES: Submit comments on or before February 25, 2013. ADDRESSES: A copy of this ICR with applicable supporting documentation; including a description of the likely respondents, proposed frequency of response, and estimated total burden may be obtained from the RegInfo.gov Web site, http://www.reginfo.gov/ public/do/PRAMain, on the day following publication of this notice or by contacting Michel Smyth by telephone at 202–693–4129 (this is not a toll-free number) or sending an email to DOL_PRA_PUBLIC@dol.gov. Submit comments about this request to the Office of Information and Regulatory Affairs, Attn: OMB Desk Officer for DOL–ETA, Office of Management and Budget, Room 10235, 725 17th Street NW., Washington, DC 20503, Fax: 202–395–6881 (this is not a SUMMARY: E:\FR\FM\25JAN1.SGM 25JAN1

Agencies

[Federal Register Volume 78, Number 17 (Friday, January 25, 2013)]
[Notices]
[Page 5503]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-01592]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances, Notice of Registration; 
Morton Grove Pharmaceuticals

    By Notice dated September 25, 2012, and published in the Federal 
Register on October 2, 2012, 77 FR 60144, Morton Grove Pharmaceuticals, 
6451 Main Street, Morton Grove, Illinois 60053-2633, made application 
by letter to the Drug Enforcement Administration (DEA) to be registered 
as a bulk manufacturer of Gamma Hydroxybutyric Acid (2010), a basic 
class of controlled substance listed in schedule I.
    The company plans to manufacture the listed controlled substance 
for distribution to its customers.
    No comments or objections have been received. DEA has considered 
the factors in 21 U.S.C. 823(a), and determined that the registration 
of Morton Grove Pharmaceuticals to manufacture the listed basic class 
of controlled substance is consistent with the public interest at this 
time. DEA has investigated Morton Grove Pharmaceuticals to ensure that 
the company's registration is consistent with the public interest. The 
investigation has included inspection and testing of the company's 
physical security systems; verification of the company's compliance 
with state and local laws; and a review of the company's background and 
history.
    Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 
CFR 1301.33, the above named company is granted registration as a bulk 
manufacturer of the basic class of controlled substance listed.

    Dated: January 14, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 2013-01592 Filed 1-24-13; 8:45 am]
BILLING CODE 4410-09-P